21 related articles for article (PubMed ID: 17661339)
1. Identification of the metabolites of ivermectin in humans.
Tipthara P; Kobylinski KC; Godejohann M; Hanboonkunupakarn B; Roth A; Adams JH; White NJ; Jittamala P; Day NPJ; Tarning J
Pharmacol Res Perspect; 2021 Feb; 9(1):e00712. PubMed ID: 33497030
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of the metabolites of sinomenine using liquid chromatography combined with benchtop Orbitrap mass spectrometry and nuclear magnetic resonance spectroscopy.
Fang K; Ren S; Zhang Q
Rapid Commun Mass Spectrom; 2024 Feb; 38(3):e9669. PubMed ID: 38211350
[TBL] [Abstract][Full Text] [Related]
3. Chromatographic assays of drug oxidation by human cytochrome P450 3A4.
Sohl CD; Cheng Q; Guengerich FP
Nat Protoc; 2009; 4(9):1252-7. PubMed ID: 19661995
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic defluorination of a terminally monofluorinated pentyl moiety: oxidative or hydrolytic mechanism?
Haschimi B; Willecke F; Mundinger S; Hüttel W; Jessen H; Müller M; Auwärter V
Drug Metab Dispos; 2024 Feb; ():. PubMed ID: 38408868
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Divergent Metabolic Pathways in Elucidating an Unexpected, Slow-Forming, and Long Half-Life Major Metabolite of Iclepertin.
Chan TS; Byer-Alcorace AJ; Latli B; Liu P; Maw HH; Raymond KG; Scaringella YS; Teitelbaum AM; Wang T; Whitcher-Johnstone A; Taub ME
Pharm Res; 2023 Aug; 40(8):1901-1913. PubMed ID: 37280472
[TBL] [Abstract][Full Text] [Related]
6. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
Prakash C; Wang W; O'Connell T; Johnson KA
Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
[TBL] [Abstract][Full Text] [Related]
7. In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms.
Xu L; Woodward C; Khan S; Prakash C
Drug Metab Dispos; 2012 Apr; 40(4):680-93. PubMed ID: 22217465
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
Obach RS
Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
[TBL] [Abstract][Full Text] [Related]
9. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
Prakash C; O'Donnell J; Khojasteh-Bakht SC
Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of sanguinarine in human and in rat: characterization of oxidative metabolites produced by human CYP1A1 and CYP1A2 and rat liver microsomes using liquid chromatography-tandem mass spectrometry.
Deroussent A; Ré M; Hoellinger H; Cresteil T
J Pharm Biomed Anal; 2010 Jul; 52(3):391-7. PubMed ID: 19804952
[TBL] [Abstract][Full Text] [Related]
11. Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry.
Prakash C; Lin J; Colizza K; Miao Z
Rapid Commun Mass Spectrom; 2007; 21(17):2822-32. PubMed ID: 17661339
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the metabolites of irisflorentin by using ultra-high performance liquid chromatography combined with quadrupole/orbitrap tandem mass spectrometry.
Zhang X; Qiao GX; Zhao GF; Zhao SF
J Pharm Biomed Anal; 2021 Sep; 203():114222. PubMed ID: 34214765
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
